StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly UpdatesOct 14, 2026, 06:06 AM

Evotec SE Preliminary Nine-Month Results Above Expectations; Reaffirms Guidance

AI Summary

Evotec SE announced preliminary unaudited financial results for the first nine months of 2026, which exceeded market expectations. The company reported Group revenues of approximately €465.0 million and adjusted Group EBITDA of approximately -€42.8 million for the period. Evotec also reaffirmed its full-year 2026 guidance for Group revenues and adjusted Group EBITDA. Full financial results for the third quarter and nine months of 2026 are scheduled for release on November 5, 2026.

Key Highlights

  • Evotec SE reports preliminary nine-months 2026 Group revenues of approximately €465.0 million.
  • Preliminary nine-months 2026 adjusted Group EBITDA is approximately -€42.8 million.
  • Evotec reaffirms full-year 2026 Group revenue guidance of €570 to €610 million.
  • Full-year 2026 adjusted Group EBITDA guidance reaffirmed at -€70 to -€105 million.